{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-121628","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.502983+00:00","generated_at":"2026-06-26T04:18:42.726246+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Repligen Q1 revenue $206.4M (+45% YoY); lowers FY2022 revenue guidance on COVID decline","bullets":["Record Q1 revenue of $206.4M (+45% YoY); GAAP EPS $0.81, adjusted EPS $0.92.","Base business grew 37% YoY; gene therapy revenue up >100%.","FY2022 revenue guidance lowered to $770-800M (from $800-830M) due to lower COVID demand.","Base business revenue growth guidance raised to 24%-31% (from 20%-22%).","Cash $584.6M at quarter end; gross margin improved 190 bps to 60.1%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-121628","json":"https://secwatch.observer/filing/0001193125-22-121628.json","markdown":"https://secwatch.observer/filing/0001193125-22-121628.md","text":"https://secwatch.observer/filing/0001193125-22-121628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312522121628/0001193125-22-121628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312522121628/d342731d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:18:42.726246+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}